Peptides > Cardiogen

Cardiogen (Bioregulator)

Cardiogen is a bioregulatory peptide with significant impacts on various body tissues, including the heart and prostate. Furthermore, it shows promise in the treatment of specific cancer types, notably sarcoma. Its most prominent advantages are observed in cases of heart attack, hypertension, and chronic heart failure. Cardiogen not only provides its own benefits but also complements existing treatments, creating a synergistic effect.

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.


1. What is Cardiogen?


2. Cardiogen Structure


3. Cardiogen and the Heart


Cardiogen, a short peptide recognized for its bioregulatory properties, primarily affects fibroblasts—cells responsible for tissue repair and scarring across the body. While much attention has focused on Cardiogen’s role in various cardiovascular conditions, its capacity to modify fibroblast behavior offers potential advantages in diverse tissues. Furthermore, Cardiogen appears to exhibit synergy with standard therapies, enhancing their effectiveness, improving long-term results, and minimizing adverse effects. Early studies in rat models even hint at Cardiogen’s potential to boost apoptosis rates in cancer cells.

Cardiogen Structure


Molecular Formula: C18H31N7O9
Molecular Weight: 489.5 g/mol
PubChem CID: 11583989
Alternative Names: SCHEMBL3194515

Cardiogen and the Heart

Cardiogen and the Heart

Within the heart, Cardiogen seems to stimulate the proliferation of cardiomyocytes while limiting the growth and development of fibroblasts. This unique action results in reduced scar formation and improved long-term outcomes, particularly in cases of cardiac remodeling leading to heart failure. Moreover, Cardiogen at a 20mg dosage may decrease p53 protein expression, leading to lower rates of apoptosis in cardiac cells[1].

Cardiogen and Cancer

Although Cardiogen reduces apoptosis in heart cells by down-regulating p53 expression, its impact on tumor cells appears to be the opposite. Research conducted on rat models with M-1 sarcoma suggests that Cardiogen administration increases apoptosis levels in tumor cells. Notably, this effect varies with dosage, indicating its genuine biological effect[2]. Cardiogen’s potential to enhance apoptosis in tumor cells, especially with an enhanced and unusual vascular supply, makes it a candidate for targeted cancer treatment. Additionally, if it can enhance the effects of standard cancer treatments, as seen in heart disease treatment, it could become a potent tool in the fight against cancer.

Cardiogen and the Prostate

Research using tissue cultures has demonstrated that Cardiogen and similar peptides can alter the expression of signaling factors in prostate fibroblasts. These signaling factors play a crucial role in creating a favorable microenvironment within tumors and may contribute to both the development and progression of prostate cancer. Studies have revealed that aging and senescent fibroblasts exhibit substantial changes in the synthesis of these markers, possibly explaining the prevalence of prostate cancer in older men and its rarity in younger individuals[3]. Remarkably, Cardiogen has the ability to normalize the levels of these signaling molecules, potentially serving as a preventive measure for prostate cancer and aiding in its control once it has developed[4].

Cardiogen in Summary

Cardiogen 20mg, though less extensively researched compared to some other bioregulators, exhibits potent effects on various body tissues, including the heart and prostate. It also holds promise in cancer treatment, particularly in cases of sarcoma. Currently, Cardiogen’s primary benefits seem to be in addressing heart conditions such as heart attack, hypertension, and chronic heart failure. What sets Cardiogen apart is its ability to complement established treatments, offering improved therapeutic outcomes.

Cardiogen is associated with minimal side effects, boasts good oral and excellent subcutaneous bioavailability in mice. It is important to note that the mouse-based dosage does not scale directly to humans. For this reason, Cardiogen is available for purchase at Peptide Sciences exclusively for educational and scientific research purposes, with no intent for human consumption. It is restricted to licensed researchers only.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.


The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.